1157 related articles for article (PubMed ID: 12414634)
61. Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells.
Borrelli MJ; Schoenherr DM; Wong A; Bernock LJ; Corry PM
Cancer Res; 2001 Feb; 61(3):1113-21. PubMed ID: 11221841
[TBL] [Abstract][Full Text] [Related]
62. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
63. Transgene expression in zebrafish: A comparison of retroviral-vector and DNA-injection approaches.
Linney E; Hardison NL; Lonze BE; Lyons S; DiNapoli L
Dev Biol; 1999 Sep; 213(1):207-16. PubMed ID: 10452858
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
65. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors.
Ma Y; Ramezani A; Lewis R; Hawley RG; Thomson JA
Stem Cells; 2003; 21(1):111-7. PubMed ID: 12529558
[TBL] [Abstract][Full Text] [Related]
66. Targeted transgene expression in rat brain using lentiviral vectors.
Jakobsson J; Ericson C; Jansson M; Björk E; Lundberg C
J Neurosci Res; 2003 Sep; 73(6):876-85. PubMed ID: 12949915
[TBL] [Abstract][Full Text] [Related]
67. A comparative evaluation of gene transfer into blood cells using the same retroviral backbone for independent expression of the EGFP and deltaLNGFR marker genes.
Giaretta I; Madeo D; Bonaguro R; Cappellari A; Rodeghiero F; Giorgio P
Haematologica; 2000 Jul; 85(7):680-9. PubMed ID: 10897118
[TBL] [Abstract][Full Text] [Related]
68. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
[TBL] [Abstract][Full Text] [Related]
69. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer].
Yang Q; Yang G; Wei L; Jia F; Wu M; Guo Y
Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):775-9. PubMed ID: 12126551
[TBL] [Abstract][Full Text] [Related]
70. Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells.
Levy JP; Muldoon RR; Zolotukhin S; Link CJ
Nat Biotechnol; 1996 May; 14(5):610-4. PubMed ID: 9630952
[TBL] [Abstract][Full Text] [Related]
71. Gene transfer system derived from the caprine arthritis-encephalitis lentivirus.
Mselli-Lakhal L; Guiguen F; Greenland T; Mornex JF; Chebloune Y
J Virol Methods; 2006 Sep; 136(1-2):177-84. PubMed ID: 16797087
[TBL] [Abstract][Full Text] [Related]
72. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
[TBL] [Abstract][Full Text] [Related]
73. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy.
Diaz RM; Bateman A; Emiliusen L; Fielding A; Trono D; Russell SJ; Vile RG
Gene Ther; 2000 Oct; 7(19):1656-63. PubMed ID: 11083474
[TBL] [Abstract][Full Text] [Related]
74. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer.
Blesch A
Methods; 2004 Jun; 33(2):164-72. PubMed ID: 15121171
[TBL] [Abstract][Full Text] [Related]
75. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
Casado E; Gomez-Navarro J; Yamamoto M; Adachi Y; Coolidge CJ; Arafat WO; Barker SD; Wang MH; Mahasreshti PJ; Hemminki A; Gonzalez-Baron M; Barnes MN; Pustilnik TB; Siegal GP; Alvarez RD; Curiel DT
Clin Cancer Res; 2001 Aug; 7(8):2496-504. PubMed ID: 11489832
[TBL] [Abstract][Full Text] [Related]
76. In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectors.
Marodon G; Klatzmann D
BMC Immunol; 2004 Aug; 5():18. PubMed ID: 15318949
[TBL] [Abstract][Full Text] [Related]
77. Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR.
Jiang L; Rampalli S; George D; Press C; Bremer EG; O'Gorman MR; Bohn MC
Gene Ther; 2004 Jul; 11(13):1057-67. PubMed ID: 15152187
[TBL] [Abstract][Full Text] [Related]
78. Development of lentiviral vectors for antiangiogenic gene delivery.
Shichinohe T; Bochner BH; Mizutani K; Nishida M; Hegerich-Gilliam S; Naldini L; Kasahara N
Cancer Gene Ther; 2001 Nov; 8(11):879-89. PubMed ID: 11773978
[TBL] [Abstract][Full Text] [Related]
79. Quantitative evaluation of the murine B16 melanoma tumor model after gene marking with an EGFP/Neo expressing retroviral vector.
Hansen BD; Duch M; Hokland P; Pedersen FS; Hokland M
In Vivo; 2002; 16(3):167-74. PubMed ID: 12182111
[TBL] [Abstract][Full Text] [Related]
80. Lentiviral vectors: regulated gene expression.
Kafri T; van Praag H; Gage FH; Verma IM
Mol Ther; 2000 Jun; 1(6):516-21. PubMed ID: 10933976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
